Kollagunta Chandrasekhar, MD
Cardiovascular Disease · Winter Haven, FLNPI 1396713491
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.5%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Novartis at 39.5% of the total. Reporting peaked in 2019 at $10,159 and has fallen 89.2% since, to $1,094 in 2025. Among cardiovascular disease clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 474 payments — averaging $45.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$9K
- Novo Nordisk$3K
- AstraZeneca$1K
- Medtronic$1K
- Johnson & Johnson$851
- Merck$747
- plus $6K from 34 others
Across 14 payments — averaging $9288.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bard Peripheral Vascular, Inc.$58K
- Amgen$25K
- Boehringer Ingelheim$15K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$14K
- AstraZeneca$11K
- Boehringer Ingelheim Pharma GmbH & Co.kg$3K
- plus $3K from 1 others
What the payments were for
- Consulting fees$2,71313%
- Speaking & faculty fees$7,84036%
- Food & beverage$10,46148%
- Education$5573%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 30 | $8,524 |
| Novo Nordisk | 6 | $2,788 |
| AstraZeneca | 56 | $1,180 |
| Medtronic(2 entities) | 48 | $1,063 |
| Johnson & Johnson | 32 | $851 |
| Merck | 34 | $747 |
| Astellas Pharma US Inc | 18 | $724 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 34 | $596 |
| Boston Scientific | 24 | $584 |
| Boehringer Ingelheim | 32 | $536 |
| Abiomed | 6 | $534 |
| Cvrx, Inc. | 10 | $495 |
| E.r. Squibb & Sons, L.L.C. | 28 | $442 |
| Pfizer | 24 | $427 |
| Abbott | 15 | $311 |
| Esperion Therapeutics, Inc. | 8 | $228 |
| Amgen | 14 | $212 |
| Stryker | 3 | $150 |
| Osprey Medical Inc | 1 | $150 |
| Impulse Dynamics (USA) Inc. | 1 | $125 |
| Portola Pharmaceuticals, LLC | 1 | $116 |
| Actelion Pharmaceuticals US, Inc. | 7 | $98 |
| Alnylam Pharmaceuticals Inc. | 5 | $86 |
| Nuwellis, Inc. | 6 | $74 |
| Lexicon Pharmaceuticals, Inc. | 4 | $73 |
| Scpharmaceuticals Inc. | 3 | $72 |
| Bayer | 3 | $53 |
| Baxter Healthcare | 3 | $51 |
| Cardiovascular Systems Inc. | 3 | $41 |
| Biosense Webster, Inc. | 2 | $39 |
| Philips North America LLC | 2 | $36 |
| Lilly USA, LLC | 2 | $35 |
| Angiodynamics, Inc. | 1 | $21 |
| Heartflow, Inc. | 2 | $19 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Bracco Diagnostics Inc. | 1 | $18 |
| Shockwave Medical, Inc | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| Biotronik Inc. | 1 | $13 |
| Bardy Diagnostics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENTRESTO$8,156
- Ozempic$2,713
- Impella$423
- XARELTO$347
- Barostim Neo System$325
- OPTIMIZER$250
- DyeVert$150
- MAKO$133
- Claria MRI$125
- VERQUVO$120
- ANDEXXA$116
- NEXLIZET$112
- NEXLETOL$112
- Reveal LINQ$111
- JARDIANCE$108
- LUX-Dx Insertable Cardiac Monitor$106
- FARXIGA$102
- LOKELMA$102
How this compares
$21,571 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 607 | $660,542 |
| EliquisApixaban | 499 | $420,842 |
| JardianceEmpagliflozin | 262 | $241,477 |
| XareltoRivaroxaban | 260 | $233,640 |
| FarxigaDapagliflozin Propanediol | 158 | $128,121 |
| Repatha SureclickEvolocumab | 14 | $7,466 |
| InpefaSotagliflozin | 11 | $7,165 |
| BrilintaTicagrelor | 12 | $7,133 |
| Midodrine Hcl | 37 | $5,164 |
| Metoprolol Succinate | 345 | $3,551 |
| Ranolazine ErRanolazine | 38 | $3,268 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 14 | $2,694 |
| Carvedilol | 391 | $2,464 |
| Diltiazem 12hr ErDiltiazem Hcl | 13 | $2,309 |
| Amiodarone Hcl | 81 | $2,100 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $8,524 | $660,542607 claims |
| PfizerEliquis | $427 | $420,842499 claims |
| Boehringer IngelheimJardiance | $536 | $241,477262 claims |
| Johnson & JohnsonXarelto | $851 | $233,640260 claims |
| AstraZenecaFarxiga, Brilinta | $1,180 | $135,254170 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $73 | $7,16511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Winter Haven
- Zaheed TaiWinter Haven$123K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.